Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 33Breast Neoplasms 27Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 19Ovarian Neoplasms 19Lung Neoplasms 18Fallopian Tube Neoplasms 18Neoplasm Metastasis 15Squamous Cell Carcinoma of Head and Neck 12Endometrial Neoplasms 10Neoplasms 9Oropharyngeal Neoplasms 6Mouth Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Melanoma 5Colorectal Neoplasms 5Carcinoma 5Adenocarcinoma Of Esophagus 5Stomach Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Transitional Cell 4Anatomic Stage I Breast Cancer AJCC v8 4Pancreatic Adenocarcinoma 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Squamous Cell 3

Interventions

Gemcitabine 5Taxes 3Albumin-Bound Paclitaxel 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2Oxaliplatin 2Losartan 2Leucovorin 2Irinotecan 2Fluorouracil 2130-nm albumin-bound paclitaxel 2tocilizumab 1selicrelumab 1niraparib 1durvalumab 1dehydroftorafur 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Standard of Care 1Specimen Handling 1Radiation 1Panitumumab 1Pancreaticoduodenectomy 1PEGPH20 1Optical Imaging 1Nivolumab 1Metformin 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × Taxes × 1 year × Clear all
NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Big Ten Cancer Research Consortium

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

Phase 1 Active not recruiting
21 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡